Catalyzing Sarcopenia Drug Development: Identifying Outcomes, Defining Disease
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.